Vericel Sees Unusually Large Options Volume (NASDAQ:VCEL)


Share on StockTwits

Vericel Co. (NASDAQ:VCEL) saw unusually large options trading on Monday. Investors acquired 1,024 call options on the stock. This is an increase of approximately 1,607% compared to the average volume of 60 call options.

A number of brokerages recently weighed in on VCEL. TheStreet upgraded shares of Vericel from a “c” rating to a “b-” rating in a research report on Wednesday, February 24th. LADENBURG THALM/SH SH raised their target price on shares of Vericel from $27.50 to $44.00 and gave the company a “buy” rating in a research note on Tuesday, January 19th. BTIG Research raised their target price on shares of Vericel from $45.00 to $56.00 in a research note on Monday, February 22nd. Oppenheimer cut shares of Vericel from an “outperform” rating to a “market perform” rating in a research report on Monday, January 11th. Finally, Truist lifted their price objective on shares of Vericel from $40.00 to $60.00 in a research report on Tuesday, February 16th. Three investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $48.63.

Shares of Vericel stock opened at $62.06 on Tuesday. The business’s fifty day simple moving average is $56.18 and its 200 day simple moving average is $39.09. The firm has a market capitalization of $2.86 billion, a P/E ratio of -6,206,000.00 and a beta of 3.11. Vericel has a 12 month low of $12.82 and a 12 month high of $64.89.

Vericel (NASDAQ:VCEL) last issued its earnings results on Tuesday, February 23rd. The biotechnology company reported $0.25 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.20 by $0.05. The firm had revenue of $45.23 million for the quarter, compared to analyst estimates of $45.05 million. Vericel had a return on equity of 0.13% and a net margin of 0.12%.

In other news, CEO Dominick Colangelo sold 40,000 shares of the business’s stock in a transaction on Monday, April 19th. The stock was sold at an average price of $58.01, for a total transaction of $2,320,400.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Jonathan Mark Hopper sold 17,924 shares of the business’s stock in a transaction on Tuesday, March 30th. The stock was sold at an average price of $51.40, for a total value of $921,293.60. Following the sale, the insider now owns 27,966 shares of the company’s stock, valued at approximately $1,437,452.40. The disclosure for this sale can be found here. Insiders have sold a total of 97,924 shares of company stock worth $5,282,094 in the last three months. 4.30% of the stock is owned by insiders.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Nisa Investment Advisors LLC lifted its position in Vericel by 302.3% during the fourth quarter. Nisa Investment Advisors LLC now owns 2,595 shares of the biotechnology company’s stock valued at $80,000 after buying an additional 1,950 shares during the period. Perigon Wealth Management LLC bought a new stake in shares of Vericel during the 4th quarter valued at about $106,000. Lazard Asset Management LLC grew its stake in shares of Vericel by 53.7% during the 4th quarter. Lazard Asset Management LLC now owns 3,460 shares of the biotechnology company’s stock valued at $106,000 after acquiring an additional 1,209 shares during the period. Rollins Financial bought a new position in shares of Vericel during the 4th quarter valued at approximately $154,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in Vericel by 33.0% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,172 shares of the biotechnology company’s stock valued at $191,000 after buying an additional 1,531 shares in the last quarter. 93.11% of the stock is owned by institutional investors.

About Vericel

Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, and distributes cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns.

Further Reading: Limitations of the P/E Growth ratio

Receive News & Ratings for Vericel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vericel and related companies with MarketBeat.com's FREE daily email newsletter.